FGFR3 and neoplasm: MiR-99 was reported to mediate down-regulation of mTOR/FGFR3 and suppress tumor growth; miR-100 is known to inhibit mTOR signaling and enhance sensitivity to Everolimus in clear cell ovarian cancer (Nagaraja et al., 2010; Oneyama et al., 2011); and mTORC1 was recently reported to regulate miR-1 in skeletal myogenesis (Sun et al., 2010).